Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Groups request DRI for omega-3s

This article was originally published in The Tan Sheet

Executive Summary

A consortium of nine scientific, trade and consumer advocacy groups tries to raise support - and funds - for the Institute of Medicine to establish clear dietary reference intakes for EPA and DHA omega-3 fatty acids. IOM needs $1 million to $1.5 million to convene an expert panel to review the fatty acids DRI, says the Global Organization for EPA and DHA Omega-3s in a Nov. 9 release. Along with the Council for Responsible Nutrition, it urges firms to support its IOM petition by visiting 1www.omega3petition.org. GOED notes that a recent issue of PLoS Medicine identified EPA and DHA inadequacy as the sixth leading cause of preventable death in the United States. It adds that establishing DRI for EPA and DHA could save billions in health care costs if consumers know how much of the omega-3s to consume to improve brain and heart health
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS103549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel